Baicalin Reduces Renal Inflammation in Mesangial Proliferative Glomerulonephritis through Activation of Nrf2/ARE and

Xiaoyuan Ning1, Dongping Luo1, Yong Chen1

  • 1Department of Nephrology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, 471003 Luoyang, Henan, China.

Discovery Medicine
|June 5, 2023
PubMed
Abstract

Insights

Baicalin, derived from Scutellaria baicalensis, effectively treats mesangial proliferative glomerulonephritis (MPGN) by reducing inflammation and cell proliferation. It activates key cellular pathways, offering a promising therapeutic approach for kidney disease.

Area of Science:

  • Nephrology
  • Pharmacology
  • Cell Biology

Background:

  • Mesangial proliferative glomerulonephritis (MPGN) is a common kidney disease characterized by mesangial cell proliferation and inflammation.
  • Baicalin, a compound from Scutellaria baicalensis, shows potential kidney-protective effects, but its role in MPGN is not well-established.

Purpose of the Study:

  • To investigate the therapeutic effects of Baicalin on Mesangial proliferative glomerulonephritis (MPGN).
  • To elucidate the underlying molecular mechanisms by which Baicalin exerts its effects on MPGN.

Main Methods:

  • In vivo: Sprague-Dawley rats were induced with MPGN and treated with varying doses of Baicalin or benazepril. Assessed urinary protein, BUN, SCr, lipids, cytokines, renal pathology, and apoptosis.
  • In vitro: Mesangial cells were stimulated with LPS and treated with Baicalin. Assessed cell viability, cell cycle, proliferation, cytokine release, and protein expression related to apoptosis, Nrf2/ARE, and PI3K/AKT pathways.

Main Results:

  • Baicalin significantly reduced urinary protein, BUN, SCr, lipids, and pro-inflammatory cytokines in MPGN rats, improving renal pathology and reducing apoptosis.
  • In vitro, Baicalin inhibited LPS-induced mesangial cell proliferation, induced G1 cell cycle arrest, and decreased inflammatory cytokine levels.
  • Baicalin treatment upregulated Nrf2 and HO-1, and downregulated p-PI3K/PI3K and p-AKT/AKT ratios, indicating activation of Nrf2/ARE and PI3K/AKT pathways.

Conclusions:

  • Baicalin demonstrates significant therapeutic potential in mitigating Mesangial proliferative glomerulonephritis (MPGN).
  • The mechanism involves the inhibition of mesangial cell proliferation and inflammation via activation of the Nrf2/ARE and PI3K/AKT signaling pathways.